about
Getting under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in PsoriasisEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Treatments for mild-to-moderate recalcitrant plaque psoriasis: expected clinical and economic outcomes for first-line and second-line care.Update on biologic safety for patients with psoriasis during pregnancy.Conditioned pharmacotherapeutic effects: a preliminary study.Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne.Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris.Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities.The validity of the diagnostic code for hidradenitis suppurativa in an electronic databaseIL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesisAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis.Briakinumab.Quality of life considerations in psoriasis treatment.Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage.Workforce characteristics of mohs surgery fellows.Clobetasol propionate foam in the treatment of psoriasis.The psychosocial burden of psoriasis.Striae gravidarum.Reporting of ethical review of clinical research submitted to the Journal of the American Academy of Dermatology.Biologicals in the treatment of psoriasis.From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.Fate of manuscripts declined by the Journal of the American Academy of Dermatology.A single-blinded, randomized pilot study to evaluate the effect of exercise-induced sweat on truncal acne.Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology.HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.Survey research in dermatology: guidelines for success.Pregnancy outcomes in psoriasis: why do we know so little?Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis.Psoriasis epidemiology: the interplay of genes and the environment.Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.Management of hidradenitis suppurativa wounds with an internal vacuum-assisted closure device.Psoriasis and the life cycle of persistent life effects.OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active compaSystemic associations of hidradenitis suppurativa.Hidradenitis suppurativa: Epidemiology and scope of the problem.
P50
Q26766463-F110C8C9-95C2-4051-9A61-191EFBBB5C23Q28280453-38C13DDC-130E-4077-B3D9-1052B67E48F9Q31151381-51865AE7-F61A-4493-B9AB-30DBE3F451F3Q33641685-8732C68D-0422-4F73-B3D8-343E5A6A9E1FQ33772537-5D272ABD-F190-4954-AF04-D8A596213FAAQ34116633-23F89AA7-15A3-4C18-BA8B-0F3EE93FC2B8Q34130313-BDE16A4F-00E4-41B5-A69E-5A281896BE5FQ34422175-960B3D97-8A46-4A43-A7F1-005E95CF5DB5Q34434622-D4EE7A7D-939B-4112-BB99-A111190C4C44Q34451023-7A96E1B5-956F-4BD5-BD4A-68D61DB4392CQ34577866-BFBF8C1F-D2C0-4F5D-B762-9D2E855B04ABQ34583765-8B15F85C-6A11-4775-AA5D-E135FCA5F676Q34611085-9A1FC681-FA3F-4FC7-84C8-E9E9FA70638AQ34990097-3E098E22-CDB8-416D-82DD-8E98B399665BQ35129060-E62646B4-A1DD-42EF-9B11-7B15CED65A19Q35583172-1E7793C4-F2D5-4F9B-936E-F41FD7BE659FQ35645946-EE9BD885-22B8-462B-B10E-4B6B5B549096Q36222073-9AB259CD-5F0A-4502-BE92-4985C7E8CA95Q36338648-12DA4B5E-AFD4-4D35-8F1D-4C8113AEFD77Q36400357-E4C385B1-F17E-4DDE-9C9E-587946057A94Q36708589-F8351208-6201-411A-8915-9D96FC6C9AB1Q36989650-D92D25FF-CF41-4C55-A4EC-ABCA78600802Q36990993-759C1397-E627-44C4-A423-85B5AF09735AQ37027264-D16740BC-6745-4621-9343-4D52C8086D2CQ37067150-7B949F19-FD97-4894-A974-A295EBF9C5B5Q37077019-B90027D5-5FBF-4A9F-934D-C5DD3480A73EQ37096194-CC7DA711-16D0-4E2C-87A9-8064249853ECQ37255501-959EB64D-B0E4-47B7-84F6-3549A3DD0456Q37279315-7AF124A0-646B-4E9A-BBA3-F808E0C92A56Q37404954-0E34FD3C-6025-4235-A323-1F631C78BD62Q37555021-D10E590A-424B-42F4-84FF-A50280A3715DQ37671840-176C7574-322E-40F5-BC40-1561126E1E6FQ38074063-80DE06A6-6D75-4790-A6CA-F00A51BAA352Q38083089-EDD0F872-546F-43B4-BC11-56A716ACC0F2Q38191399-0DF7D91E-D35B-4240-9FC8-FFD078971694Q38269970-45A94ABF-2B4E-4660-AC27-52048BD89413Q38545195-32BBA8C0-E446-4F83-B1A2-54F8E86332AFQ38558538-66235EE4-93FA-4BCA-AEB8-07C27CE4D1FEQ38607971-4EEC8EDA-B030-4DEA-9B63-BF75E9131A0AQ38607976-86150A5B-3E0C-4ED0-9502-85B66A451997
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexandra Boer Kimball
@ast
Alexandra Boer Kimball
@en
Alexandra Boer Kimball
@es
Alexandra Boer Kimball
@nl
type
label
Alexandra Boer Kimball
@ast
Alexandra Boer Kimball
@en
Alexandra Boer Kimball
@es
Alexandra Boer Kimball
@nl
prefLabel
Alexandra Boer Kimball
@ast
Alexandra Boer Kimball
@en
Alexandra Boer Kimball
@es
Alexandra Boer Kimball
@nl
P214
P106
P214
P31
P496
0000-0001-9405-0479
P7859
lccn-n2004009619